Brief: Gensight Biologics: LUMEVOQ Continues To Show Promise As Novel Therapy For ND4-LHON

Gensight Biologics SA

15/12/2022 06:37

Dec 15 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES PUBLICATION OF INDIRECT
COMPARISON
OF LUMEVOQ® VERSUS NATURAL HISTORY IN ND4-LHON PATIENTS IN
PEER-REVIEWED JOURNAL OPHTHALMOLOGY AND THERAPY
    * 90% OF EYES TREATED WITH LUMEVOQÒ ON-CHART 4 YEARS AFTER
THEIR
VISION LOSS
    * LUMEVOQÒ CONTINUES TO SHOW PROMISE AS A NOVEL THERAPY FOR
TREATMENT OF ND4-LHON

Source text for Eikon:  ID:nBw5VPkkfa 
Further company coverage:  SIGHT.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))